Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study

समान संसाधन

• P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI
  द्वारा: M Mateos, और अन्य
  प्रकाशित: (2023-05-01)
• Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study
  द्वारा: Fredrik H. Schjesvold, और अन्य
  प्रकाशित: (2024-02-01)
• AndroDex: Android Dex Images of Obfuscated Malware
  द्वारा: Sana Aurangzeb, और अन्य
  प्रकाशित: (2024-02-01)
• Cyclophosphamide addition to pomalidomide/dexamethasone is not necessarily associated with universal benefits in RRMM.
  द्वारा: Hyunkyung Park, और अन्य
  प्रकाशित: (2022-01-01)
• Author Correction: AndroDex: Android Dex Images of Obfuscated Malware
  द्वारा: Sana Aurangzeb, और अन्य
  प्रकाशित: (2024-07-01)